246 related articles for article (PubMed ID: 27894215)
1. The molecular pathogenesis of mantle cell lymphoma.
Vogt N; Dai B; Erdmann T; Berdel WE; Lenz G
Leuk Lymphoma; 2017 Jul; 58(7):1530-1537. PubMed ID: 27894215
[TBL] [Abstract][Full Text] [Related]
2. Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis.
Quintanilla-Martinez L; Davies-Hill T; Fend F; Calzada-Wack J; Sorbara L; Campo E; Jaffe ES; Raffeld M
Blood; 2003 Apr; 101(8):3181-7. PubMed ID: 12515730
[TBL] [Abstract][Full Text] [Related]
3. Role of SOX11 and Genetic Events Cooperating with Cyclin D1 in Mantle Cell Lymphoma.
Beà S; Amador V
Curr Oncol Rep; 2017 Jun; 19(6):43. PubMed ID: 28466437
[TBL] [Abstract][Full Text] [Related]
4. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
[TBL] [Abstract][Full Text] [Related]
5. Flipping the cyclin D1 switch in mantle cell lymphoma.
Hasanali Z; Sharma K; Epner E
Best Pract Res Clin Haematol; 2012 Jun; 25(2):143-52. PubMed ID: 22687450
[TBL] [Abstract][Full Text] [Related]
6. Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV.
de Vos S; Krug U; Hofmann WK; Pinkus GS; Swerdlow SH; Wachsman W; Grogan TM; Said JW; Koeffler HP
Diagn Mol Pathol; 2003 Mar; 12(1):35-43. PubMed ID: 12605034
[TBL] [Abstract][Full Text] [Related]
7. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma.
Shishodia S; Amin HM; Lai R; Aggarwal BB
Biochem Pharmacol; 2005 Sep; 70(5):700-13. PubMed ID: 16023083
[TBL] [Abstract][Full Text] [Related]
8. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.
Pérez-Galán P; Dreyling M; Wiestner A
Blood; 2011 Jan; 117(1):26-38. PubMed ID: 20940415
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways.
Fernàndez V; Hartmann E; Ott G; Campo E; Rosenwald A
J Clin Oncol; 2005 Sep; 23(26):6364-9. PubMed ID: 16155021
[TBL] [Abstract][Full Text] [Related]
10. Do mantle cell lymphomas have an 'Achilles heel'?
Saba N; Wiestner A
Curr Opin Hematol; 2014 Jul; 21(4):350-7. PubMed ID: 24857884
[TBL] [Abstract][Full Text] [Related]
11. Gene methylation and silencing of SOCS3 in mantle cell lymphoma.
Molavi O; Wang P; Zak Z; Gelebart P; Belch A; Lai R
Br J Haematol; 2013 May; 161(3):348-56. PubMed ID: 23432547
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.
Restelli V; Chilà R; Lupi M; Rinaldi A; Kwee I; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Nov; 6(35):37229-40. PubMed ID: 26439697
[TBL] [Abstract][Full Text] [Related]
13. Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach.
Chaturvedi NK; Rajule RN; Shukla A; Radhakrishnan P; Todd GL; Natarajan A; Vose JM; Joshi SS
Mol Cancer Ther; 2013 Oct; 12(10):2006-17. PubMed ID: 23963361
[TBL] [Abstract][Full Text] [Related]
14. Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma.
Klener P
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500350
[TBL] [Abstract][Full Text] [Related]
15. A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma.
Beltran E; Fresquet V; Martinez-Useros J; Richter-Larrea JA; Sagardoy A; Sesma I; Almada LL; Montes-Moreno S; Siebert R; Gesk S; Calasanz MJ; Malumbres R; Rieger M; Prosper F; Lossos IS; Piris MA; Fernandez-Zapico ME; Martinez-Climent JA
Proc Natl Acad Sci U S A; 2011 Jul; 108(30):12461-6. PubMed ID: 21746927
[TBL] [Abstract][Full Text] [Related]
16. Toll-Like Receptor 1/2 and 5 Ligands Enhance the Expression of Cyclin D1 and D3 and Induce Proliferation in Mantle Cell Lymphoma.
Mastorci K; Muraro E; Pasini E; Furlan C; Sigalotti L; Cinco M; Dolcetti R; Fratta E
PLoS One; 2016; 11(4):e0153823. PubMed ID: 27123851
[TBL] [Abstract][Full Text] [Related]
17. Novel targeted therapeutics for mantle cell lymphoma--what's on the horizon?
El Halabi L; Ghez D; Ribrag V
Expert Rev Hematol; 2016 Mar; 9(3):271-81. PubMed ID: 26689790
[TBL] [Abstract][Full Text] [Related]
18. Identification of V-ATPase as a molecular sensor of SOX11-levels and potential therapeutic target for mantle cell lymphoma.
Emruli VK; Olsson R; Ek F; Ek S
BMC Cancer; 2016 Jul; 16():493. PubMed ID: 27430213
[TBL] [Abstract][Full Text] [Related]
19. Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in MCL patients independent of CCND1.
Teo AE; Chen Z; Miranda RN; McDonnell T; Medeiros LJ; McCarty N
Leukemia; 2016 Mar; 30(3):580-93. PubMed ID: 26073757
[TBL] [Abstract][Full Text] [Related]
20. Molecular Pathogenesis of Mantle Cell Lymphoma.
Navarro A; Beà S; Jares P; Campo E
Hematol Oncol Clin North Am; 2020 Oct; 34(5):795-807. PubMed ID: 32861278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]